WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue results for the second quarter of 2007. The Company expects to record total revenues of approximately $15 – $16 million in the second quarter of 2007, compared to $4.6 million in total revenues in the second quarter of 2006, prior to the acquisition of ANTARA® (fenofibrate) capsules in August 2006. During the second quarter of 2007, the Company expects to record approximately $14 million in revenue from ANTARA and approximately $1.5 million in revenues from FACTIVE® (gemifloxacin mesylate) tablets.
